Vertaling van "trial results " (Nederlands → Frans) :

The results of these trials are concordant with previous trials, except one where bupropion was evaluated in an unmotivated population.
The results of these trials are concordant with previous trials, except one where Bupropion was evaluated in an unmotivated population.

62. Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL, et al. Randomized trial of breast self-examination in Shanghai: final results.
61. Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL, et al. Randomized trial of breast self-examination in Shanghai: final results.

16. Miller A, Baines C, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years.
17. Miller A, Baines C, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years.

Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P en Versavel M. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neurlagia: results of a randomised, placebo-controlled clinical trial.
Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P et Versavel M. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.

Blomstedt G.C. , Kytta J. Results of a randomized trial of vancomycin prophylaxis in craniotomy.
Blomstedt G.C. , Kytta J. Results of a randomized trial of vancomycin prophylaxis in craniotomy .

The extension is the result of a major amendment to the application to include an additional 12 months of data to provide a median of five years of follow up of the pivotal Austrian Breast & Colorectal Cancer Study Group Trial 12 (ABCSG-12).
Cette prolongation est le résultat d’une modification importante de l’utilisation destinée à inclure des données portant sur douze mois de manière à fournir une moyenne sur cinq ans de suivi de l'essai pivot dénommé «Austrian Breast & Colorectal Cancer Study Group Trial 12» (ABCSG-12) sur le cancer du sein et du côlon.

A Phase III trial of Tasigna as a third-line therapy for GIST did not meet its primary endpoint, but results showed a two-month improvement in median overall survival (not statistically significant) for patients treated with Tasigna.
Un essai de phase III de Tasigna comme traitement de troisième ligne des GIST n’a pas satisfait au critère principal, mais les résultats ont montré une amélioration sur deux mois de la survie médiane globale (non significative statistiquement) des malades traités avec Tasigna.

In October 2009, results from the global ENESTnd trial, the largest head-to-head comparison of a targeted therapy against Glivec ever conducted, showed that Tasigna produced faster and deeper responses than Glivec in newly diagnosed CML patients.
En octobre 2009, des résultats de l’essai ENESTnd réalisé à l’échelle mondiale, la plus vaste confrontation jamais entreprise entre un traitement ciblé et Glivec, ont montré que Tasigna provoquait des réponses plus rapides et plus profondes que Glivec chez les malades souffrant d'une LMC apparue récemment.

In 2005, we participated in an industry-wide effort to improve transparency by creating an online portal, disclosing results from more than 250 000 clinical trials conducted worldwide.
En 2005, nous avons participé à une opération conjointe de tous les acteurs de notre branche en vue d’améliorer la transparence sur les essais cliniques. Un portail Internet a été créé, recensant les résultats de plus de 250’000 essais cliniques conduits à travers le monde.